Novartis Corporation Says Buys Intercell AG Encephalitis Drug
ZURICH, June 13 (Reuters) - Swiss drugmaker Novartis has bought the rights to market IC51, a late-stage drug for the prevention of Japanese Encephalitis virus infections from Austrian biotech firm Intercell .